Our work is entirely funded by private donations – we receive no money from government. Your money will help us continue funding research into vitiligo and supporting people affected by the condition.
GIA632 antibody treatment for nonsegmental vitiligo
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase IIb Study to Assess the Efficacy and Safety of GIA632 in Adult Participants With Non-segmental Vitiligo Followed by an Extension Period
Status: Recruiting now
Description:
Novartis Pharmaceuticals plans to enroll about 210 participants. The experimental antibody blocks IL-15, an immune signal that helps pigment-destroying T cells survive. Researchers hope it will reduce the immune attack on melanocytes and allow skin color to return. Possible risks include injection or infusion reactions, headache, and infections; longer-term risks are still being studied. People ages 18 to 99 may qualify. The study is recruiting at 72 listed sites across 12 countries.
Start date: March 09, 2026
Completion date: January 28, 2030
Organizer: Novartis Pharmaceuticals
Contact: Novartis Pharmaceuticals
Tel.: 1-888-669-6682
Email: novartis.email@novartis.com
Clinical Trial Alerts
Sign up and be the first to know about updates on this trial.
FAQOther Questions
- Polypodium leucotomos as an adjunct treatment for vitiligo?
The tropical fern Polypodium leucotomos (also known as Polypodium aureum) and its relative Polypodium decumanumhave shown potential benefits for managing vitiligo and other auto...
- Can chemicals cause vitiligo?
Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...
- Can Ginkgo Biloba help with vitiligo?
Ginkgo Biloba offers a promising, simple, and relatively affordable option for managing vitiligo. Known for its anti-inflammatory, immunomodulatory, and antioxidant properties, ...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.